                               NIH Public Access
                               Author Manuscript
                               Mol Microbiol. Author manuscript; available PMC 2010 27.
                           Published final edited form 
NIH-PA Author Manuscript




                            Mol Microbiol. 2008 April ; 68(1): 37â€“50. doi:10.1111/j.1365-2958.2008.06131.x.



                           Characterization Trypanosoma brucei dihydroorotate
                           dehydrogenase possible drug target; structural, kinetic                            RNAi studies

                           Tracy L Arakaki*,1,2, Frederick S Buckner*,2,3, J Robert Gillespie3, Nicholas Malmquist4,
                           Margaret Phillips4, Oleksandr Kalyuzhniy1,2, Joseph R Luft2,5, George T DeTitta2,5,
                           Christophe L M J Verlinde1,2, Wesley C Van Voorhis2,3, Wim G J Hol1,2, Ethan                            Merritt1,2,â€ 
                           1Department Biochemistry, University Washington, Seattle, WA 98195 USA

                           2Structural   Genomics Pathogenic Protozoa (SGPP), www.sgpp.org
                           3Department      Medicine, University Washington, Seattle, WA 98195 USA
NIH-PA Author Manuscript




                           4Department Pharmacology, University Texas Southwestern Medical Center, Dallas, TX 75390

                           USA
                           5Hauptman      Woodward Institute, Buffalo, NY USA

                           Abstract
                                 Nucleotide biosynthesis pathways reported essential protozoan pathogens.
                                  evaluated essentiality enzyme pyrimidine biosyn-thetic pathway,
                                 dihydroorotate dehydrogenase (DHODH) eukaryotic parasite Trypanosoma brucei                                  gene knockdown studies. RNAi knockdown DHODH expression bloodstream-form T. brucei
                                 did inhibit growth normal medium, profoundly retarded growth pyrimidine-depleted
                                 media presence known pyrimidine uptake antagonist 5-fluoruracil (5-FU).                                  results significant implications development therapeutics combat T. brucei
                                 infection. Specifically, combination therapy including T. brucei-specific DHODH inhibitor plus
                                 5-FU prove effective therapeutic strategy. trypanosomal enzyme
                                 inhibited known inhibitors bacterial Class 1A DHODH, distinction sensitivity                                  DHODH human higher eukaryotes. selectivity supported crystal
NIH-PA Author Manuscript




                                 structure T. brucei enzyme, reported resolution 1.95 Ã…. Additional research,
                                 guided crystal structure described  needed identify potent inhibitors T. brucei
                                 DHODH.


                           Keywords
                                 flavoprotein; pyrimidine biosynthesis; gene knockdown; kinetoplastid; RNAi


                           INTRODUCTION
                                            Pyrimidine biosynthesis vital biological process, achieved novo synthesis                                             pyrimidine salvage pathways.  parasitic protozoa deficient pyrimidine

                           â€ 
                            Correspondence  Ethan Merritt, Dept Biochemistry, Box 357742, University Washington, Seattle, WA 98195. Phone: (206)
                           543-1421; Fax: (206) 685-7002; merritt@u.washington.edu.
                           *Contributed equally
                            Arakaki et al.                                                                                              Page 2


                                            salvage (Chaudhary Roos, 2005) enzymes pyrimidine synthesis pathway
                                            considered potential drug targets. fourth enzyme pathway                                             dihydroorotate dehydrogenase (DHODH), oxidizes dihydroorotate orotate, NIH-PA Author Manuscript




                                            aromatic intermediate pathway, consequent transfer electrons protein
                                            cofactor FMN (Figure 1). Recent experiments validate DHODH drug target                                             Trypanosoma cruzi showed insect-stage epimastigotes dependent novo synthesis
                                            pyrimidines (Annoura et al., 2005). Specifically, gene interruption gene loci
                                            encoding cytosolic DHODH T. cruzi led cell non-viability; addition pyrimidine
                                            nucleosides medium did rescue DHODH knockdown cells.                                             undertook extensive investigation essentiality closely homologous gene
                                            T. brucei, causative agent African Sleeping Sickness.

                                            DHODHs categorized classes, Class 1 Class 2, based sequence,
                                            localization cell, electron acceptor used reoxidize FMN second half-
                                            reaction (Nielsen, Andersen Jensen, 1996; Nielsen, Rowland, Larsen Jensen, 1996).
                                            classes belong Pfam sequence family PF01180. Class 1 DHODHs primarily
                                            bacterial. cytosolic divided 1A (E.C. 1.3.3.1) 1B (E.C. 1.3.1.14)
                                            depending electron acceptor oligomeric state. Class 2 DHODHs, including                                             human plasmodial enzymes, monomeric contain mitochondrial targeting sequences
                                            located N-terminal domain (Rowland et al., 2000). Furthermore,                                             inner membrane mitochondria (Knecht et al., 1996) associated cytoplasmic
NIH-PA Author Manuscript




                                            membranes case E. coli (Karibian, 1978). Specific inhibitors known                                             classes (Palfey et al., 2001; Baldwin et al., 2005).

                                            present genomic, biochemical, structural evidence TbDHODH Class 1A
                                            DHODH, particular inhibited Class 1A specific inhibitors. structural
                                            analysis based 1.95Ã… resolution crystal structure T. brucei enzyme crystallized
                                            reaction product orotate. present kinetic, inhibition, biophysical, RNAi
                                            knockdown data T. brucei DHODH, previously characterized.
                                            Furthermore RNAi knockdown T. brucei DHODH synergistic                                             effects 5-fluorouracil (5-FU), inhibitor pyrimidine uptake T. brucei  Koning                                             Jarvis, 1998). finding provides rationale develop DHODH inhibitors                                             used combination 5-FU inhibitor pyrmidine uptake yield potent
                                            regimen. encouraged structure inhibition studies offer insight                                             stereochemical functional details active site trypanosomal enzyme,                                             facilitate development lead compounds anti-trypanosomal drug discovery.                                             results essentiality enzyme divergent reported closely
                                            related T. cruzi parasite, underscore importance validating anti-protozoan drug
                                            targets separately target organism (Wang,1997).
NIH-PA Author Manuscript




                              RESULTS
                                            DHODH gene T. brucei genome (GeneDB Tb927.5.3830).                                             gene initially identified structural genomics target (TargetDB Tbru015978)                                             Structural Genomics Pathogenic Protozoa consortium (SGPP). time work                                             initiated trypanosomal DHODH structures available, preliminary
                                            characterization Leishmania major DHODH presented (Feliciano et al., 2006)                                             preliminary crystallization T. cruzi enzyme reported (Inaoka et al., 2005).                                             undertook novo crystallographic structure determination T. brucei DHODH,                                             undertook biochemical characterization enzyme confirm assignment                                             trypanosomal enzymes Class 1A.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                             Page 3


                              Structural analysis
                                            crystal structure TbDHODH determined 1.95Ã… resolution single crystal
                                            space group C2221. Consistent previously determined structures sequence
NIH-PA Author Manuscript




                                            family, overall fold TbDHODH monomer Î±Î² barrel prosthetic FMN
                                            group located near C-terminus (Figure 2a).

                                            asymmetric unit crystal structure contains monomers arranged                                             distinct dimers. monomers dimer related fold symmetry dimer
                                            overlays L. lactis 1A dimer. area contact dimer interface 2300
                                            Ã…2 analyzed PDBsum (Laskowski et al., 2005). interface includes 19 inter-monomer
                                            hydrogen bonds salt bridge Glu208 monomer Lys297 monomer B.
                                            salt bridge observed L. lactis structure. Lys297 strictly conserved                                             Class 1A DHODHs; residue 208 conserved glutamate aspartate (Fig. S2). 
                                            salt bridge characteristic feature dimer interface Class 1A DHODHs.

                                            oligomeric state protein examined analytical ultracentrifugation. TbD-
                                            HODH observed protein absorption 280 nm FMN absorption 454 nm.
                                            centrifugation experiments, single ideal species model consistently yielded                                             average mass indicative dimeric enzyme, monomer/dimer model reliably produced
                                            sub-micromolar dissociation constants dimerization (Fig. S1). biophysical result
                                            supports crystallographic observation TbDHODH homodimer.
NIH-PA Author Manuscript




                                            TbDHODH structure contains cis-peptides, Glu56-Pro57 Cys193-Val194.                                             cis-peptides observed structures L. lactis 1A, L. lactis 1B, human Class
                                            2 homologs. residues following cis-peptide, Arg58 Tyr59, close
                                            proximity active site highly conserved Class 1A DHODH sequences.                                             exceptional stereochemistry observed refined TbDHODH model.

                              FMN binding site
                                            FMN prosthetic group located near dimer interface pocket formed predominantly
                                            strands Î²4, Î²6â€“7, Î²11, Î²17. FMN forms hydrogen bonds residues Ala20, Ser45,
                                            Lys44, Cys249, Val194, Lys165 (Fig. S3); hydrophobic interactions residues
                                            Ala19, Gly21, Met70, Tyr59, Asn68, orotate. isoalloxazine ring FMN                                             aromatic ring orotate parallel DHODH-orotate structures.                                             dimethylbenzene moiety isoalloxazine ring lacks close contacts residue
                                            solvent accessible. differs FMN binding site human structure (25 
                                            sequence identity), Class 2-specific N-terminal domain blocks access active
                                            site. similar hydrogen bonding interactions FMN TbDHODH NIH-PA Author Manuscript




                                            human structures residues conserved structures Lys44
                                            Cys249. sulfhydryl Cys249 forms hydrogen bond O3 ribityl group                                             FMN. equivalent interaction absent human structure,                                             hydrogen bond O3. sequence-based structure alignment, Lys44 glycine human
                                            structure nearby lysine (hLys100), forms hydrogen bonds O4                                             isoalloxazine ring plays role binding FMN.

                                            residues TbDHODH form hydrophobic interactions FMN,                                             different human protein. differences potential use designing                                             inhibitor targeting FMN binding site differential specificity human                                             trypanosomal enzymes.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                               Page 4


                              Orotate binding site conserved motifs Class 1A DHODH
                                            Class 1 Class 2 DHODHs differ active site base responsible abstraction                                             proton C5 orotate. Class 1A DHODHs base cysteine; Class 2 enzymes,
NIH-PA Author Manuscript




                                            including human DHODH, serine (NÃ¸rager et al., 2003). TbDHODH, SÎ³ active
                                            site base Cys131 3.65 Ã… away C5 orotate. distance slightly longer                                             3.3 Ã… observed L. lactis DHODH:orotate structure. present crystal structure pH
                                            4 cysteine sulfur likely protonated. Residues 126â€“143, spanning region                                             active site Cys, strongly conserved Class 1A DHODHs (Fig. S2).
                                            residues described pyrimidine binding motif: EZNLSCPNZPUKZQXXYD,
                                            U polar uncharged residue, X non-specific residue hydrophobic
                                            residue.

                                            structure-based sequence alignment T. brucei, L. lactis 1B, human DHODHs,
                                            representing Classes 1A, 1B 2, respectively, shows Class 1 sequences                                             insertion 15 residues (residues 202â€“216) relative human Class 2 sequence (Figure 3).
                                            residues form strand-loop-strand-loop (Î²14-loop-Î²15-loop) structural unit. Residues
                                            195â€“203 preceding insertion conserved Class 1A DHODHs form                                             NSXGNGLXI motif (1A motif 1) close proximity active site. Asn195                                             conserved Asn residues interact orotate.

                                            orotate binding site flanked loop consisting residues 132â€“138 (Fig. S4). NIH-PA Author Manuscript




                                            loop highly conserved Class 1A DHODHs (Fig. S2). crystal structures human
                                            DHODH corresponding loop poorly ordered, loop flexibility hypothesized allow
                                            active site open dihydroorotate enter orotate exit (Liu et al., 2000).
                                            contrast human structure, loop present TbDHODH structure relatively
                                            closed conformation defined electron density.  orotate FMN
                                            binding sites accessible TbDHODH human structure absence
                                            N-terminal domain characteristic Class 2 DHODH (Figure 2). difference                                             accessibility contribute differential sensitivity Class 1A Class 2 enzymes
                                            orotate analogues hydroxybenzoate.

                              RNA interference studies T. brucei DHODH
                                            Gene expression knockdown T. brucei DHODH achieved expressing                                             stem-loop RNA target gene bloodstream form T. brucei. Messenger RNA levels                                             decreased 95  72 hours following induction RNA interference construct                                             addition tetracycline (Figure 4a). Knockdown T. brucei DHODH protein appeared                                             similarly substantial observed Western blots. monitored seven days,                                             protein levels detected <5  levels observed RNAi induction (Figure 4b). NIH-PA Author Manuscript




                                            T. brucei cells grown standard medium (HMI-9), growth rates cells RNAi
                                            turned (TCN+) turned (TCNâˆ’) comparable (Figure 5a). growth rates
                                            cultures virtually control cells (â€™single-markerâ€™) containing                                             T7 RNA polymerase Tet repressor genes maintained neomycin marker.                                             surprising observation normal cell growth led investigate parasites surviving
                                            scavenging pyrimidines medium. Note HMI-9 medium includes 16 ÂµM
                                            thymidine. additional thymidine omitted medium, saw                                             change growth phenotype induction RNA interference DHODH (data
                                            shown). standard medium 10  fetal bovine serum, repeated
                                            experiment using commercially available dialyzed serum, depleted small
                                            molecules pyrimidines. conditions observed reduced growth                                             induction RNAi construct. day 4 growth rate significantly reduced                                             arrested day 6 (Figure 5b). cells expressing RNAi construct                                             pyrimidine-depleted medium took bloated, balloon-shaped morphology day 5. 

                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                                 Page 5


                                            small degree growth suppression TCNâˆ’ cells compared single-marker
                                            controls, leaky expression RNAi construct.
NIH-PA Author Manuscript




                                            proceeded test RNAi knockdown DHODH impair growth
                                            standard medium inhibitor pyrimidine uptake present. 5-fluorouracil (5-
                                            FU) tested shown potent inhibitor pyrimidine uptake T.
                                            brucei (Gudin et al., 2006). inhibitory concentration 5-FU causing 50  growth
                                            inhibition (IC50) shifted 16-fold lower parasites undergoing knockdown DHODH
                                            (IC50 = 0.64 ÂµM) compared parasites undergoing knockdown (IC50 = 10.4 ÂµM) using
                                            standard medium (Figure 6). follow finding, tested uptake 3H-5-FU                                             DNA T. brucei cells observed uptake 2-fold higher                                             DHODH-knockdown parasites controls (Figure 7).

                              Classification TbDHODH Class 1A inhibition hydroxybenzoates
                                            TbDHODH activity examined presence standard DHODH terminal
                                            electron acceptors (Figure 8) catalyze fumarate efficiently, typical                                             Family 1A enzymes (Andersen et al., 1994). enzyme catalyzes reduction menadione
                                            (vitamin K3) ~20  rate fumarate catalysis, does appear perform electron
                                            transfer menaquinone (vitamin K2), ubiquinone analogues Q0, Q1, Q2, QD,                                             NAD+, characteristics Family 1A DHODH enzyme (Nara et al., 2000;Nielsen,
                                            Andersen Jensen, 1996;Marcinkeviciene et al., 2000). Catalysis DHO fumarate
NIH-PA Author Manuscript




                                            displays saturation kinetics Km values 14 ÂµM DHO 80 ÂµM fumarate                                             Vmax 8.5 sâˆ’1 (Figure 9). pH dependence enzyme activity assayed (Figure 9 inset)
                                            peak activity occur pH 7.8, indicative ionizable groups pKa
                                            values 6.3 9.2 involved substrate binding catalysis. Analysis TbDHODH
                                            activity range DHO fumarate concentrations produces double-reciprocal plot
                                            parallel lines (Figure 10), indicative ping-pong mechanism consistent results
                                            Family 1A enzymes (Marcinkeviciene et al., 2000).

                                            Inhibition TbDHODH benzoate pyrimidine analogues initially performed 1
                                            mM inhibitor (data shown). benzoate pyrimidine analogues tested, 3,4-                                             3,5-dihydroxybenzoate displayed inhibition 1 mM concentration. Subsequent analysis                                             TbD-HODH inhibition 3,4- 3,5-dihydroxybenzoate various inhibitor DHO
                                            concentrations (Figure 11) revealed competitive inhibition 3,4-dihydroxybenzoate                                             Ki ~58 ÂµM (determined IC50 plot, shown) weaker inhibition 3,5-
                                            dihydroxybenzoate, appeared non-competitive yielded Ki 200 ÂµM. values
                                            comparable reported Class 1A DHODHs (Feliciano et al., 2006; Takashima
                                            et al., 2002).
NIH-PA Author Manuscript




                              DISCUSSION
                              Divergent pyrimidine requirement T. cruzi T. brucei
                                            Trypanosoma brucei genome contains enzymes required novo pyrimidine
                                            biosynthesis, indicating T. brucei capable providing pyrimidine pools
                                            (Berriman, 2004). fourth enzyme pathway, DHODH, considered potential
                                            drug target parasitic protozoa including P. falciparum T. cruzi (McRobert                                             McConkey, 2002; Annoura et al., 2005; Baldwin et al., 2005). particular, Class 1A
                                            DHODH T. cruzi shown gene disruption experiments necessary                                             growth epimastigotes (Annoura et al., 2005). performed functional, enzymatic,                                             structural studies protein related parasite T. brucei, causative agent African
                                            sleeping sickness, attempt confirm similar essentiality.



                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                                Page 6


                                            Functional studies using RNA interference block TbDHODH revealed bloodstream T.
                                            brucei able grow normally enzyme, apparently scavenging pyrimidines
                                            medium (Figure 5). ability scavenge pyrimidines entirely unexpected,
NIH-PA Author Manuscript




                                            shown T. brucei surface transporters capable importing uracil                                             cytosine  Koning Jarvis, 1998;Papageorgiou et al., 2005;Gudin et al., 2006). addition,
                                            T. brucei genome contains enzymes associated pyrimidine salvage,
                                            including cytidine deam-inase (GeneDB Tb09.160.1680), uracil phosphoribosyltransferase
                                            (GeneDB Tb927.4.3320), thymidine kinase (GeneDB Tb10.70.7270).

                                             T. brucei, chemotherapeutic strategy deprive cells pyrimidine pools                                             appear require inhibition pyrimidine biosynthesis pyrimidine uptake/salvage.
                                            tested feasibility pronged attack repeating DHODH RNAi
                                            knockdown experiments presence 5-FU, compound previously demonstrated                                             inhibit pyrimidine uptake T. brucei (Gudin et al., 2006). 5-FU itself cytotoxic high
                                            concentrations inhibition thymidylate synthase incorporation DNA RNA
                                             Bono Twelves, 2001). observed cells undergoing dual treatment                                             affected DHODH knockdown, 16-fold sensitive 5-FU control
                                            cells (Figure 6). suggests cells tolerate inhibition pyrimidine
                                            synthesis inhibition pyrimidine uptake.

                                            5-FU inhibits pyrimidine uptake T. brucei, itself transported cells NIH-PA Author Manuscript




                                            relatively high efficiency (Gudin et al., 2006). possible cellular response suppression
                                            pyrimidine biosynthesis, case interference DHODH, regulate
                                            import pathway. follow experiment performed determine relative
                                            uptake radiolabelled 5-FU DNA T. brucei cells presence absence                                             DHODH suppression. experiment demonstrated >2x higher 5-FU incorporation                                             DHODH knockdown cells controls (Figure 7). likely increased
                                            incorporation 5-FU DNA partly account enhanced sensitivity drug.
                                            speculate increased incorporation 5-FU DNA DHODH knockdown
                                            cells results following factors: 1) depletion intracellular
                                            pyrimidine pools favors incorporation 5-FU, 2) possible regulation enzymes
                                            convert 5-FU 5-fluorouracil monophosphate (FUMP), 5-fluorouracil diphosphate
                                            (FUDP), 5-fluorouracil triphosphate (FUTP), 3) possible increased uptake 5-FU                                             regulated pyrimidine transporter activity cell surface. Future experiments                                             necessary better establish mechanisms responsible observations.

                                            Whichever mechanisms play, apparent synergy DHODH
                                            knockdown plus 5-FU treatment significant implications pursuing pyrimidine
                                            biosynthesis pathway drug target T. brucei. imagine combination treatment
NIH-PA Author Manuscript




                                            including 5-FU new compound specifically inhibits T. brucei DHODH                                              possibly enzyme pyrimidine biosynthesis pathway). new DHODH inhibitor
                                            â€œchemosensitizerâ€? 5-FU dramatically enhance activity 5-
                                            FU treating T. brucei infection. 5-FU established clinical drug use
                                            1950â€™s. known toxicities, certainly advantages existing
                                            human African trypanosomiasis drugs (e.g. melarso-prol, suramin, pentamidine, )                                             extremely toxic require parenteral administration. important develop partner
                                            drug inhibits T. brucei DHODH selectively. human DHODH Class 2
                                            enzyme functionally structurally distinct Class 1 T. brucei enzyme,                                             expect finding selective inhibitors quite feasible. data presented provide                                             strong rationale pursuing research T. brucei DHODH order develop
                                            potent inhibitors drug leads.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                               Page 7


                              Inhibitors trypanosomal Class 1A DHODH
                                            previous focus inhibitor studies largely directed Class 2 DHODHs. P.
                                            falciparum enzyme (PfDHODH) focus significant potential new
NIH-PA Author Manuscript




                                            target development anti-malarials (Baldwin et al., 2005), human enzyme                                             targeted treatment cancer, gastric ulcers, rheumatoid arthritis (Palfey et al., 2001).
                                            Structural studies PfDHODH inhibitors based brequinar analogues (Boa et al., 2005),
                                            biphenylamides (Baldwin et al., 2005), A771726 (HeikkilÃ¤ et al., 2006), atovaquone (Hansen
                                            et al., 2004), lefluno-mide (Hurt et al., 2006) analogues bind similarly,
                                            attacking ubiquinone binding site formed jointly N- C-terminal domains (Figure
                                            2c). Unfortunately, given involvement Class 2-specific N-terminal domain, class
                                            inhibitors unlikely relevant Class 1 enzymes.

                                             inhibitors specific Class 1A enzymes known, including
                                            hydroxybenzoates. orotate analogs shown specifically inhibit                                             L. lactis Class 1A DHODH minimal effect L. lactis Class 1B enzyme human
                                            E. coli Class 2 enzymes (Palfey et al., 2001). stereochemistry protein
                                            residues forming orotate binding site Class 1A Class 2 enzymes nearly identical,
                                            redox mechanism differs classes (Fagan et al., 2007). Fagan et al. (2007)                                             attributed subtle dynamic features proteins. basis present structure,
                                            suggest features include differential access orotate FMN sites                                               protein (Figure 2) difference relative mobility observed
NIH-PA Author Manuscript




                                            crystallographically residues 132â€“138 pyr-binding motif (Figure 3).

                                            Wolfe et al. (2007) investigated structural details kinetics hydroxybenzoate
                                            inhibition L. lactis Class 1A DHODH. inhibitor observed crystallographically
                                            monomer homodimer, consistent kinetic data showing cooperativity
                                            monomers dimer. structural basis cooperativity                                             evident (Wolfe et al., 2007). Given high structural conservation L. lactis
                                            structure present T. brucei structure, plausible class inhibitors
                                            relevant trypanosomal homologs. shown inhibition assays
                                            TbDHODH hydroxybenzoate inhibitors act bacterial DHODHs                                             Class 1A DHODH eukaryotic parasite. particular, competitive
                                            inhibition 3,4-dihydroxybenzoate (Ki 58 ÂµM) non-competitive inhibition 3,5-
                                            dihydroxybenzoate (Ki 200 ÂµM). Ki values higher reported L.
                                            lactis remain possible starting points anti-parasitic drug design.

                              Applicability inhibitor design pathogens
                                            T. brucei representative larger class pathogenic protozoan parasites responsible NIH-PA Author Manuscript




                                            substantial burden human disease. evaluating importance TbDHODH possible
                                            drug target, drugs acting TbDHODH                                             effective related pathogens. Class 1A DHODHs primarily bacterial,                                             acquired yeasts (Saccharomyces, Kluyveromyces) apparently                                             lateral gene transfer Lactococcus (Hall et al., 2005). appearance Class 1A DHODH
                                            trypanosomatids similarly lateral transfer, point introduction
                                            clade protozoan lineages known.

                                            sequences T. brucei Class 1A, L. lactis Class 1B, P. falciparum Class 2 DHODH
                                            submitted GeneDB omni-BLAST server (Hertz-Fowler et al., 2004)                                             homologs protozoa. species contain DHODH class.
                                            protozoan Class 1B homologs detected. Plasmodium genomes contain Class
                                            2 sequences. sequences T. brucei, T.b. gambiense, T. cruzi, T. congolense, T. vivax,
                                            L. major, L. infantum >75  sequence identity genome strain TbDHODH. 

                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                             Page 8


                                            residues involved binding FMN orotate conserved, suggesting drug design based
                                            TbDHODH structure relevant pathogenic trypanosomatids.
NIH-PA Author Manuscript




                              Summary
                                            shown RNAi interference dihydroorotate dehydrogenase bloodstream
                                            form Trypanosoma brucei inhibits growth access pyrimidines environment                                             blocked. calls question general essentiality pyrimidine biosynthesis
                                            pathway T. brucei, distinction previous report essentiality T. cruzi. 
                                            shown RNAi suppression DHODH synergistic effect                                             complementary growth-blocking agent 5-FU, inhibits pyrimidine uptake.                                             demonstrates interference T. brucei DHODH potentiate activity                                             established clinical drug 5-FU bloodstream form T. brucei.

                                            crystal structure enzymatic properties T. brucei enzyme active site
                                            similar Class 1A DHODHs Class 2 DHODHs higher
                                            eukaryotes, including human DHODH. Encouragingly, inhibited hydroxybenzoates,                                             common Class 1A DHODHs distinction Class 2 human DHODH.

                                            T. brucei DHODH, extension enzymes pyrimidine biosynthetic
                                            pathway, remains possible target development pronged therapeutic approach
                                            attacking pyrimidine biosynthesis pyrimidine uptake. Furthermore, propose NIH-PA Author Manuscript




                                            molecular details provided present TbDHODH structure useful designing
                                            selective inhibitors potential lead compounds targeting protozoan dihydroorotate
                                            dehydrogenases.

                              MATERIALS METHODS
                              Protein expression crystallography
                                            gene encoding TbDHODH PCR amplified genomic DNA strain T.
                                            brucei TREU927 GUTat 10.1 cloned vector AVA421, based E. coli
                                            expression vector pET14b (Alexandrov et al., 2004). AVA421 vector contains cleavable
                                            N-terminal tag. protein purified using Ni-NTA column bound protein
                                            cleaved protease 3C overnight 4Â°C. released protein purified gel
                                            filtration HiLoad Superdex 200.

                              Protein expression enzymatic studies
                                            DHODH gene amplified T. brucei brucei 427 strain genomic DNA                                             polymerase chain reaction using primers 5â€™-
NIH-PA Author Manuscript




                                            CGCAAAGGGAAAAGTCATATGAGTTTGAAAGTTAAT-3â€™ 5â€™-
                                            CATCAACACCCATGTATCTCGAGATCCATCGTCTTCACGC-3â€™, introduced
                                            NdeI XhoI restriction sites. product subcloned, ligated pET22b (EMD
                                            Biosciences) providing C-terminus tag. resulting TbDHODH-pET22b plasmid                                             transformed BL21-DE3 E. coli cells, grown LB-Miller medium                                             OD600nm 0.8, supplemented 100 ÂµM FMN induced 200 ÂµM IPTG.                                             cell pellet collected 3 hours induction resuspended lysis buffer (50 mM sodium
                                            phosphate, pH 8.0, 10 mM imidazole, 5 mM 2-mercaptoethanol, 10  glycerol, 1 mg/ml
                                            lysozyme, 0.1 mg/ml DNAse) protease inhibitor cocktail added final
                                            concentration 200 ÂµM phenylmethylsulfonyl fluoride, 1 Âµg/ml leupeptin, 2 Âµg/ml antipain,
                                            10 Âµg/ml benzamidine, 1 Âµg/ml pepstatin 1 Âµg/ml chymostatin. lysis mixture                                             incubated 2 hours ice constant stirring, sonicated centrifuged 20,000 Ã— g                                             30 minutes 4Â°C. supernatant centrifugation loaded 10 ml column                                             nickel agarose resin (Qiagen) equilibrated Wash Buffer (50 mM sodium phosphate, pH


                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                              Page 9


                                            8.0, 300 mM sodium chloride, 20 mM imidazole, 5 mM 2-mercaptoethanol, 10  glycerol).
                                            column washed volumes Wash Buffer, His6-tagged protein eluted
                                            Elution Buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride, 300 mM
NIH-PA Author Manuscript




                                            imidazole, 5 mM 2-mercaptoethanol, 10  glycerol). eluted protein pooled                                             concentrated 2 ml Centriprep YM-10 centrifugal filtration device (Amicon
                                            Millipore) applied HiPrep 26/10 Desalting Column (Amersham Biosciences)
                                            equilibrated 50 mM sodium phosphate, pH 8.0, 150 mM sodium chloride, 10 
                                            glycerol. Protein containing fractions pooled concentrated 

                              Crystallization
                                            Purified TbDHODH shipped dry ice High Throughput Crystallization Screening                                             Hauptman-Woodward Medical Research Institute (Luft et al., 2003). sample                                             rapidly thawed 30Â°C water bath orotic acid (8 Âµl 200mM orotic acid stock solution)
                                            added 392 Âµl protein solution. Crystallization experiments set using                                             microbatch oil technique (Chayen et al., 1992) Robbins Scientific Tango liquid
                                            handling  1536 experiments contained 200 nl crystallization cocktail
                                            solution combined 200 nl protein solution USP grade mineral oil (Sigma cat
                                            #M1180) contained low birefringence 1536 microassay plate (Greiner BioOne cat#
                                            790801). Manual review plate images 1 week 4Â°C identified 124 crystallization
                                            conditions outcomes considered suitable optimization trials. initial hits                                             optimized crystals grown sitting drop method. Crystals used data collection grew
NIH-PA Author Manuscript




                                            drop consisting 0.4 Âµl protein solution (14.1 mg/ml), mixed 0.4 Âµl reservoir
                                            solution containing 40  PEG 1000, 0.1M Na citrate, 0.1M KBr, pH 4.0 room temperature.

                              X-ray crystal structure determination structural analysis
                                            Native crystals flash frozen directly liquid nitrogen. Data collected 1.95Ã…
                                            resolution single crystal maintained 100K, X-ray wavelength corresponding                                             bromine K edge (Î» = 0.92010Ã…), ALS beamline 8.2.1. Data processed scaled
                                            using MOSFLM CCP4 program package (Collaborative Computational Project  4,
                                            1994) automated Wedger Scaler scripts Elves (Holton Alber, 2004). Data
                                            processing statistics shown Table 1. contribution anomalous dispersion                                             ordered Br atoms measured Bragg intensities insufficient solve structure using
                                            SAD phasing, 11 partially-occupied sites later identified refined structure.
                                            structure L. lactis DHODH (PDB accession code 1jue, 51  sequence identity)
                                            submitted Swiss-model server (Guex Peitsch, 1997; Schwede et al., 2003)                                             create hybrid homology model based structure L. lactis DHODH containing
                                            TbDHODH residues. model submitted Molrep (Vagin Teplyakov, 1997),
                                            placed copies monomeric model s.u. yielding correlation
NIH-PA Author Manuscript




                                            coefficient 0.60. TbDHODH structure refined using Refmac5 (Murshudov et al.,
                                            1997) reflections 21 Ã… 1.95 Ã… resolution, keeping 5  reflections
                                            Rf ree. Model building validation accomplished using Coot (Emsley Cowtan,
                                            2004) Molprobity (Lovell et al., 2003). Electron density region orotate binding
                                            site shown Fig. S5. final model consists molecules forming dimers.                                             final model monomer consists residues 1â€“313, orotate, FMN molecule.
                                            overall model contains 11 bromide atoms, 3 glycerol molecules 638 water
                                            molecules. final model crystallographic structure factors deposited                                             Protein Data Bank (accession code 2b4g).

                              Enzyme kinetic inhibition assays
                                            Enzyme kinetic assays performed enzyme assay buffer (50 mM HEPES, pH 8.0, 150
                                            mM NaCl, 10  glycerol) 25Â°C. Analysis pH dependence utilized MES (pH 5.5â€“6.5),


                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                           Page 10


                                            MOPS (6.5â€“7.5), Tris (7.5â€“9.0), CHES (9.0â€“10.0) buffer salts place HEPES.
                                            Production orotate monitored 300 nm (Îµ300 = 2.65 mMâˆ’1cmâˆ’1) using fumarate,
                                            282 nm (Îµ282 = 6.60 mMâˆ’1cmâˆ’1) using vitamin K analogues, 296 nm (Îµ296 =
NIH-PA Author Manuscript




                                            4.30 mMâˆ’1cmâˆ’1) using ubiquinone analogues. Reduction NAD+ monitored                                             340 nm (Îµ340 = 6.22 mMâˆ’1cmâˆ’1). Strong absorption far-UV inhibitors tested
                                            required use traditional electron acceptor dichlorophenolindophenol (DCIP)                                             inhibition studies reduction DCIP followed 600 nm (Îµ600 = 18.8
                                            mMâˆ’1cmâˆ’1).

                                            DHO-dependent activity examined presence 500 ÂµM fumarate. Fumarate-
                                            dependent activity assayed constant DHO concentration 250 ÂµM. Data                                             analyzed using software package GraphPad Prism SigmaPlot fitted                                             Michaelis-Menten equation.

                                            Alternative electron acceptors (vitamin K ubiquinone analogues, NAD+) assayed                                             100 ÂµM electron acceptor (dissolved oxygen estimated ~210 ÂµM) 250 ÂµM DHO.
                                            Inhibitors initially examined 1 mM presence 25 ÂµM DHO 120 ÂµM DCIP,
                                            subsequent assays utilized 120 ÂµM DCIP various DHO inhibitor concentrations.
                                            experiments performed duplicate; combined data presented, kinetic
                                            parameters reported mean Â± standard error fit.
NIH-PA Author Manuscript




                              Analytical ultracentrifugation
                                            Analytical ultracentrifugation performed Beckman XL analytical ultracentrifuge
                                            enzyme observed 280 nm (protein) 454 nm (FMN). Enzyme samples 5â€“25
                                            ÂµM centrifuged 14000 20000 rpm 4Â°C, equilibrium sedimentation scans                                             obtained hours, equilibrium determined reached contiguous
                                            scans indistinguishable. Data fitted single ideal species model                                             monomer-dimer model representative result multiple experiments presented.

                              RNA interference
                                            region TbDHODH gene sequence selected RNAi using program RNAit
                                            (Redmond et al., 2003). Bases 413â€“859 gene amplified T. brucei 927 genomic
                                            DNA using primers 5â€™-ATACCAATGTGATGGCACAGGTCGGATATGACTTTGA-3â€™
                                            5â€™-ATACCATAGAGTTGGGTTGAGTCGAGCAAATATGATG-3â€™. amplicon                                             ligated using TA cloning vector pGEM-T (Promega, cat# A3600), excised                                             enzyme BstXI. insert ligated stem-loop RNAi vector, pQuadra3,                                             described (Inoue et al., 2005). construct sequenced verify identity                                             insert, linearized NotI preparation electroporation.
NIH-PA Author Manuscript




                                            T. brucei bloodstream-form parasites expressing T7 RNA polymerase Tet repressor
                                            single selection marker provided G. Cross (Rockefeller University) (Wirtz et
                                            al., 1999). cells grown HMI-9 10  heat-inactivated fetal bovine serum                                             37Â°C 5  CO2 G418 2.5 Âµg/ml (Hirumi Hirumi, 1989). Mid-log phase T.
                                            brucei (2.5 Ã— 107) suspended 500 Âµl cytomix (120mM KCl, 0.15 mM CaCl2, 10
                                            mM K2HPO4/KH2PO4 pH 7.6, 25 mM Hepes, 2 mM Na2EDTA, 5 mM MgCl2) containing
                                            10 Âµg NotI linearized pQuadra3/DHODH DNA. mixture electroporated 4mm
                                            gap cuvette 1.6 kV 24â„¦ resistance. Cells suspended HMI-9 medium                                             presence 2.5 Âµg/ml phleomycin 2.5 Âµg/ml G418. Individual clones selected                                             subsequent RNAi studies. expression dsRNA induced addition 1 Âµg/ml
                                            tetracycline cultures diluted 1 Ã— 105 cells/ml. Cultures passed 1:10â€“1:20
                                            dilution daily cell concentrations monitored using ATPLite Luminescence ATP
                                            detection Assay (PerkinElmer, cat #6016941).


                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                            Page 11


                                            Separate growth experiments performed using HMI-9 medium omitted thymidine
                                            (normally included 16 ÂµM). pyrimidine bases medium;                                             supplemented 100 ÂµM hypoxanthine source purines. medium NIH-PA Author Manuscript




                                            supplemented 10  dialyzed fetal bovine serum (Hyclone) complete pyrimidine
                                            depleted medium.

                              Northern analysis
                                            RNA isolated induced non-induced cultures 72 h growth using RNEasy
                                            kit (Qiagen). 16 Âµg total RNA electrophoresed formaldehyde gel blotted using
                                            standard procedures. RNA membrane analyzed DNA probe amplified
                                            genomic DNA using primers 5â€™-CTCGGACATGAGTTTTCCAACC-3â€™ 5â€™-
                                            GGCTTCCTACTGTAATCGTG 3â€™ correspond bases 22â€“281 DHODH open
                                            reading frame. blot stripped probed DNA T. brucei Î²-tubulin gene
                                            standardization.

                              IC50 shift assay
                                            Sensitivity 5-FU tested trypomastigotes single marker parent line                                             single marker cells containing pQuadra3/DHODH RNAi vector uninduced cells
                                            cells induced 48 hours 1 Âµg/ml tetracycline. Cells added 96 plates
                                            triplicate initial inoculum 2 Ã— 104 trypomastigotes  compound stock
NIH-PA Author Manuscript




                                            solution 5-fluorouracil (Sigma, F6627) prepared using sterile water initial
                                            concentration 20 mM. diluted HMI-9 concentration 120 ÂµM added
                                            serial dilutions final volume 200ul  Parasite growth quantified 48 hours
                                            addition Alamar Blue (Alamar Biosciences, DAL1100) (Raz et al., 1997).

                              5-FU incorporation experiment
                                            Incorporation 5-FU T. brucei genomic DNA measured bloodstream forms
                                            single marker parent cell line bloodstream forms containing pQuadra3/
                                            DHODH RNAi construct. Measurements taken uninduced cultures cultures
                                            induced 72 hours 1 Âµg/ml tetracycline. trypomastigotes                                             grown standard HMI-9 containing thymidine hypoxanthine, 2.5 Âµg/ml
                                            neomycin. addition, cells containing pQuadra3/DHODH RNAi vector                                             grown presence 2.5 Âµg/ml phleomycin. 72 hour induction, cells                                             transferred 96 plate pulsed 5 ÂµCi [6-3H]-5-FU (Moravek Biochemicals,
                                            MT-686) 24 hours. Cell density quantification, order standardize results,                                             30 ul sample using ATPLite Luminescence ATP detection Assay                                             (PerkinElmer, cat #6016941) described  incorporation 3H-5-FU measured
                                            binding DNA remaining 175 Âµl glass fiber filters cell harvester
NIH-PA Author Manuscript




                                            (Inotech Biosystems International, , Rockville, MD), radioactivity incorporated
                                            parasites counted Chameleon 425-104 multilabel plate scintillation counter
                                            (Hidex Oy, Turku, Finland).

                              Antibody production Western immunoblotting
                                            Purified TbDHODH sent Affinity BioReagents (Golden,  antibody production
                                            rabbits previously described (www.bioreagents.com/index.cfm/fuseaction/content.aod).
                                            Antibody specificity confirmed purified TbDHODH T. brucei cells lysates
                                            using pre-immune post-challenge serum specific. anti-TbDHODH
                                            antibodies used Western blots lysates T. brucei bloodstream form cells collected
                                            daily time intervals induction RNAi. Standard Western blot procedures
                                            followed using goat-horseradish peroxidase-conjugated secondary antibody ECL
                                            detection (Amersham Biosciences). Relative TbDHODH protein levels determined 

                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                                             Page 12


                                            densitometry. numerical values normalized stained bands transferred
                                            SDS-PAGE gel  shown).
NIH-PA Author Manuscript




                              Supplementary Material
                                            Refer Web version PubMed Central supplementary material.


                              Acknowledgments
                                            thank Jonathan Caruthers Meg Holmes aid data collection. reliant efforts                                             members SGPP consortium, including Eric Phizicky, Erin Quartley, Angela Lauricella, Lori Schoenfeld,
                                            Jennifer Ross, Frank Zucker, Thomas Earnest. thank Dr. HP Koning helpful discussions T.
                                            brucei transporter activities. work supported Protein Structure Initiative, award NIGMS GM64655;
                                            NIH award AI067921; funds Howard Hughes Medical Institute (HHMI) WGJH; National
                                            Institutes Health Grants AI053680 MAP. Portions work carried Advanced Light Source,
                                            supported Director, Office Science, Office Basic Energy Sciences, U.S. Department                                             Energy Contract  AC02-05CH11231.


                              REFERENCES
                                            Alexandrov  Vignali M, LaCount DJ, Quartley E, Vries C, Rosa DD, Babulski J, Mitchell SF,
                                               Schoenfeld LW, Fields S, Hol  Dumont  Phizicky EM, Grayhack EJ. facile method                                                high-throughput expression protein pairs. Mol Cell Proteomics 2004;3:934â€“938. [PubMed:
NIH-PA Author Manuscript




                                               15240823]
                                            Andersen PS, Jansen PJ, Hammer K. different dihydroorotate dehydrogenases Lactococcus lactis.
                                               J Bacteriol 1994;176:3975â€“3982. [PubMed: 8021180]
                                            Annoura T, Nara T, Makiuchi T, Hashimoto T, Aoki T. origin dihydroorotate dehydrogenase
                                               genes kinetoplastids, special reference biological significance adaptation                                                anaerobic, parasitic conditions. J Mol Evol 2005;60:113â€“127. [PubMed: 15696374]
                                            Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA. High-throughput
                                               screening potent selective inhibitors Plasmodium falciparum dihy-droorotate
                                               dehydrogenase. J Biol Chem 2005;280:21847â€“21853. [PubMed: 15795226]
                                            Beitz E. TEXshade: shading labeling multiple sequence alignments using LATEX2 epsilon.
                                               Bioinformatics 2000;16:135â€“139. [PubMed: 10842735]
                                            Berriman M. Data mining parasite genomes. Parasitology 2004;(128 Suppl):S23â€“S31. [PubMed:
                                               16454895]
                                            Boa  Canavan SP, Hirst PR, Ramsey C, Stead AMW, McConkey GA. Synthesis brequinar analogue
                                               inhibitors malaria parasite dihydroorotate dehydrogenase. Bioorg Med Chem 2005;13:1945â€“1967.
                                               [PubMed: 15727850]
                                            Chaudhary K, Roos DS. Protozoan genomics drug discovery. Nat Biotechnol 2005;23:1089â€“1091.
                                               [PubMed: 16151400]
NIH-PA Author Manuscript




                                            Chayen NE, Stewart PDS, Blow DM. Microbatch crystallization oil â€“ new technique allowing
                                               small-volume crystallization trials. Journal Crystal Growth 1992;122:176â€“180.
                                            Collaborative Computational Project  4. ccp4 suite: programs protein crystallography. Acta
                                                 Cryst 1994;D50:760â€“763.
                                            Bono JS, Twelves CJ. oral fluorinated pyrimidines. Invest New Drugs 2001;19(1):41â€“59.
                                                 [PubMed: 11291832]
                                            Koning HP, Jarvis SM. highly selective, high-affinity transporter uracil Trypanosoma brucei
                                                 brucei: evidence proton-dependent transport. Biochem Cell Biol 1998;76:853â€“858. [PubMed:
                                                 10353720]
                                            Emsley P, Cowtan K. Coot: model-building tools molecular graphics. Acta Cryst 2004;D60:2126â€“
                                                 2132.
                                            Fagan R, Jensen K, Bjornberg O, Palfey B. Mechanism flavin reduction class 1a dihydroorotate
                                                 dehydrogenase lactococcus lactis. Biochemistry 2007;46(13):4028â€“4036. [PubMed:
                                                 17341096]



                                                  Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                                     Page 13


                                            Feliciano PR, Cordeiro  Costa-Filho AJ, Nonato MC. Cloning, expression, purification,                                                 characterization Leishmania major dihydroorotate dehydrogenase. Protein Expr Purif 2006;48(1):
                                                98â€“103. [PubMed: 16600626]
NIH-PA Author Manuscript




                                            Guda C, Lu S, Scheeff ED, Bourne PE, Shindyalov  CE-MC: multiple protein structure alignment
                                                server. Nucleic Acids Res 2004;32:W100â€“W103. [PubMed: 15215359]
                                            Gudin S, Quashie NB, Candlish D, Al-Salabi MI, Jarvis SM, Ranford-Cartwright LC, Koning HP.
                                                Trypanosoma brucei: survey pyrimidine transport activities. Exp Parasitol 2006;114:118â€“125.
                                                [PubMed: 16620810]
                                            Guex N, Peitsch MC. SWISS-MODEL Swiss-PdbViewer: environment comparative
                                                protein modeling. Electrophoresis 1997;18:2714â€“2723. [PubMed: 9504803]
                                            Hall C, Brachat S, Dietrich FS. Contribution horizontal gene transfer evolution Saccharomyces
                                                cerevisiae. Eukaryot Cell 2005;4(6):1102â€“1115. [PubMed: 15947202]
                                            Hansen M, Nours JL, Johansson E, Antal T, Ullrich  LÃ¶ffler M, Larsen S. Inhibitor binding class
                                                2 dihydroorotate dehydrogenase causes variations membrane-associated N-terminal domain.
                                                Protein Sci 2004;13:1031â€“1042. [PubMed: 15044733]
                                            HeikkilÃ¤ T, Thirumalairajan S, Davies M, Parsons MR, McConkey AG, Fishwick CWG, Johnson AP.
                                                novo designed inhibitors Plasmodium falciparum dihydroorotate dehydrogenase.
                                                Bioorg Med Chem Lett 2006;16:88â€“92. [PubMed: 16236496]
                                            Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou  Mooney P, Tivey  Berriman M, Hall
                                                N, Rutherford K, Parkhill J, Ivens AC, Rajandream M  Barrell B. GeneDB: resource                                                 prokaryotic eukaryotic organisms. Nucleic Acids Res 2004;32:D339â€“D343. [PubMed:
NIH-PA Author Manuscript




                                                14681429]
                                            Hirumi H, Hirumi K. Continuous cultivation Trypanosoma brucei blood stream forms medium
                                                containing low concentration serum protein feeder cell layers. J Parasitol 1989;75:985â€“
                                                989. [PubMed: 2614608]
                                            Holton J, Alber T. Automated protein crystal structure determination using ELVES. Proc Natl Acad Sci
                                                U S 2004;101:1537â€“1542. [PubMed: 14752198]
                                            Hurt  Widom J, Clardy J. Structure Plasmodium falciparum dihydroorotate dehydrogenase                                                 bound inhibitor. Acta Crystallogr D Biol Crystallogr 2006;62:312â€“323. [PubMed: 16510978]
                                            Inaoka DK, Takashima E, Osanai  Shimizu H, Nara T, Aoki T, Harada S, Kita K. Expression,
                                                purification crystallization Trypanosoma cruzi dihydroorotate dehydrogenase complexed                                                 orotate. Acta Crystallograph Sect F Struct Biol Cryst Commun 2005;61:875â€“878.
                                            Inoue M, Nakamura Y, Yasuda K, Yasaka N, Hara T, Schnaufer  Stuart K, Fukuma T. 14-3-3
                                                proteins Trypanosoma brucei function motility, cytokinesis, cell cycle. J Biol Chem
                                                2005;280(14):14085â€“14096. [PubMed: 15653691]
                                            Karibian D. Dihydroorotate dehydrogenase (Escherichia coli). Methods Enzymol 1978;51:58â€“63.
                                                [PubMed: 211391]
                                            Knecht W, Bergjohann U, Gonski S, Kirschbaum B, LÃ¶ffler M. Functional expression fragment                                                 human dihydroorotate dehydrogenase means baculovirus expression vector                                                  kinetic investigation purified recombinant enzyme. Eur J Biochem 1996;240:292â€“301.
NIH-PA Author Manuscript




                                                [PubMed: 8925840]
                                            Laskowski RA, Chistyakov VV, Thornton JM. PDBsum  new summaries analyses known
                                                3D structures proteins nucleic acids. Nucleic Acids Res 2005;33:D266â€“D268. [PubMed:
                                                15608193]
                                            Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J. Structures human dihydroorotate
                                                dehydrogenase complex antiproliferative agents. Structure 2000;8:25â€“33. [PubMed:
                                                10673429]
                                            Lovell SC, Davis IW, Arendall WB, Bakker PIW, Word JM, Prisant MG, Richardson JS, Richardson
                                                DC. Structure validation Calpha geometry: phi,psi Cbeta deviation. Proteins 2003;50:437â€“
                                                450. [PubMed: 12557186]
                                            Luft JR, Collins RJ, Fehrman NA, Lauricella  Veatch CK, DeTitta GT. deliberate approach                                                 screening initial crystallization conditions biological macromolecules. J Struct Biol
                                                2003;142:170â€“179. [PubMed: 12718929]



                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                                 Page 14


                                            Marcinkeviciene J, Jiang W, Locke G, Kopcho LM, Rogers MJ, Copeland RA. second dihydroorotate
                                                dehydrogenase (Type  human pathogen Enterococcus faecalis: expression, purification,                                                 steady-state kinetic mechanism. Arch Biochem Biophys 2000;377(1):178â€“186. [PubMed:
NIH-PA Author Manuscript




                                                10775458]
                                            McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth Plasmodium falciparum. Mol
                                                Biochem Parasitol 2002;119(2):273â€“278. [PubMed: 11814579]
                                            Murshudov GN, Vagin AA, Dodson EJ. Refinement macromolecular structures maximum-
                                                likelihood method. Acta Cryst 1997;D53:240â€“255.
                                            Nara T, Hshimoto T, Aoki T. Evolutionary implications mosaic pyrimidine-biosynthetic pathway
                                                eukaryotes. Gene 2000;257:209â€“222. [PubMed: 11080587]
                                            Nielsen FS, Andersen PS, Jensen KF. B form dihydroorotate dehydrogenase Lactococcus
                                                lactis consists different subunits, encoded pyrDb pyrK genes, contains FMN,
                                                FAD, [FeS] redox centers. J Biol Chem 1996;271:29359â€“29365. [PubMed: 8910599]
                                            Nielsen FS, Rowland P, Larsen S, Jensen KF. Purification characterization dihydroorotate
                                                dehydrogenase Lactococcus lactis, crystallization preliminary X-ray diffraction studies
                                                enzyme. Protein Sci 1996;5:852â€“856. [PubMed: 8732756]
                                            NÃ¸rager S, Arent S, BjÃ¶rnberg O, Ottosen M, Leggio LL, Jensen KF, Larsen S. Lactococcus lactis
                                                dihydroorotate dehydrogenase mutants reveal important facets enzymatic function. J Biol
                                                Chem 2003;278:28812â€“28822. [PubMed: 12732650]
                                            Palfey BA, BjÃ¶rnberg O, Jensen KF. Specific inhibition family 1A dihydroorotate dehydrogenase
                                                benzoate pyrimidine analogues. J Med Chem 2001;44:2861â€“2864. [PubMed: 11520193]
NIH-PA Author Manuscript




                                            Papageorgiou IG, Yakob L, Salabi MIA, Diallinas G, Soteriadou KP, Koning HPD. Identification                                                 pyrimidine nucleobase transporter Leishmania: similarities Trypanosoma brucei U1
                                                transporter antileishmanial activity uracil analogues. Parasitology 2005;130:275â€“283.
                                                [PubMed: 15796010]
                                            Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. Alamar Blue assay determine drug
                                                sensitivity African trypanosomes (T.b. rhodesiense T.b. gambiense) vitro. Acta Trop
                                                1997;68(2):139â€“147. [PubMed: 9386789]
                                            Redmond S, Vadivelu J, Field MC. RNAit: automated web-based tool selection RNAi targets
                                                Trypanosoma brucei. Mol Biochem Parasitol 2003;128:115â€“118. [PubMed: 12706807]
                                            Rowland P, NÃ¸rager S, Jensen KF, Larsen S. Structure dihydroorotate dehydrogenase B: electron
                                                transfer flavin groups bridged iron-sulphur cluster. Structure 2000;8:1227â€“1238.
                                                [PubMed: 11188687]
                                            Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: automated protein homology-modeling
                                                server. Nucleic Acids Res 2003;31:3381â€“3385. [PubMed: 12824332]
                                            Takashima E, Inaoka DK, Osanai  Nara T, Odaka M, Aoki T, Inaka K, Harada S, Kita K.
                                                Characterization dihydroorotate dehydrogenase soluble fumarate reductase                                                 Trypanosoma cruzi. Mol Biochem Parasitol 2002;122(2):189â€“200. [PubMed: 12106873]
                                            Vagin  Teplyakov  Molrep: automated program molecular replacement. J. Appl. Cryst
                                                1997;30:1022â€“1025.
NIH-PA Author Manuscript




                                            Wang CC. Validating targets antiparasite chemotherapy. Parasitology 1997;114:S31â€“S44. Suppl
                                                (NIL). [PubMed: 9309767]
                                            Wirtz E, Leal S, Ochatt C, Cross GA. tightly regulated inducible expression conditional
                                                gene knock-outs dominant-negative genetics Trypanosoma brucei. Mol Biochem Parasitol
                                                1999;99:89â€“101. [PubMed: 10215027]
                                            Wolfe  Thymark M, Gattis S, Fagan R, Hu Y-c, Johansson E, Arent S, Larsen S, Palfey B. Interaction
                                                benzoate pyrimidine analogues class 1a dihydroorotate dehydrogenase lactococcus
                                                lactis. Biochemistry 2007;46(19):5741â€“5753. [PubMed: 17444658]




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                          Page 15
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 1.
                                            Oxidation dihydroorotate orotate.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                        Page 16
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 2.
                                            Comparison T. brucei human DHODH. TbDHODH homodimeric, typical Class
                                            1A homologues. human enzyme monomeric, characteristic Class 2 homologues.
                                              TbDHODH monomer showing Class 1A motifs: Motif 1 (residues 195â€“203, blue), Motif
                                            2 (residues 64â€“76, green), Motif 3 (residues 214â€“223, orange), Pyr-binding motif (residues
                                            126â€“143, red). orotate FMN cofactors shown brown yellow, respectively.
                                            (b) Surface representation TbDHODH, showing orotate FMN sites relatively
                                            solvent accessible loop 132â€“138 â€˜closedâ€™ conformation. (c) Surface
                                            representation entire human DHODH monomer including ordered residues (30â€“
                                            69) N-terminal domain (brown). Class 2 homologues N-terminal domain

                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                             Page 17


                                            restricts solvent access orotate FMN binding sites direction. depression
                                            visible center surface binding site Class 2 DHODH redox partner
                                            ubiquinone, Class 2 specific inhibitors brequinar. (d) Surface representation
NIH-PA Author Manuscript




                                            human DHODH N-terminal residues removed purpose comparison                                             trypanosomal enzyme.
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                          Page 18
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 3.
                                            structure-based sequence alignment Class 1A T. brucei (current structure), Class
                                            1B L. lactis (PDB accession code 1ep1), Class 2 human DHODH (PDB accession code
                                            1d3g). active site Cys131 colored yellow. Asn residues important catalysis                                             conserved classes DHODH colored cyan. Class 1A motifs                                             aid classification DHODHs labeled discussed Fig. S2. Residue
NIH-PA Author Manuscript




                                            numbering secondary structure elements correspond T. brucei DHODH.                                             alignment generated using CEMC Multiple Protein Structure Alignment Server
                                            (http://bioinformatics.albany.edu/~cemc/) (Guda et al., 2004) colored using TEXshade
                                            (Beitz, 2000). human sequence shown begins residue 69, omitting N-terminal
                                            domain present Class 1 homologues.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                              Page 19
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 4.
                                            Knockdown DHODH mRNA expression (Panel  DHODH protein expression (Panel
                                            B) induction RNAi tetracycline.  -  Northern blot T. brucei cells collected
                                            72 h post-tetracycline induction RNAi (TCN+) demonstrates 95  knockdown DHODH
                                            mRNA compared cells containing construct RNAi uninduced (TCN-).  -
                                             Î²-tubulin mRNA expression levels near-equivalent RNA loading. (B) Western
                                            blot performed cell lysates collected day 0 (pre-induction) 7 days post-
                                            induction. blot probed anti-T. brucei DHODH antibody. upper band
                                            represents binding unidentified protein affected RNAi expression. NIH-PA Author Manuscript




                                            predicted DHODH protein labelled nearly absent day induction RNAi.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                           Page 20
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 5.
                                            Gene knockdown T. brucei DHODH using RNA interference. Cumulative cell densities                                             shown log-scale product cell number total dilution.  . Cell growth
                                            monitored T. brucei undergoing RNAi DHODH (TCN+) compared cells
                                            RNAi induction (TCNâˆ’). cells grown standard media bloodstream-
                                            form T. brucei. growth rate compared "single marker" (SM) strain T.
                                            brucei transfected RNAi expression vector (semi-logarithmic plot). (B).
                                            experiment Panel repeated using pyrimidine-depleted medium.




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                           Page 21
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 6.
                                            Effects different concentrations 5-FU T. brucei cells. RNAi induced                                             tetracycline 48 h, cells incubated serial dilutions 5-FU 48 h
                                            quantified Alamar Blue. Labeling Figure 5.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                        Page 22
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 7.
                                            Incorporation (3H)5-FU T. brucei cells. RNAi induced tetracycline 72 h,
                                            cells exposed (3H)5-FU additional 24 h harvesting quantifying
                                            tritium uptake DNA. Labeling Figure 5.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                    Page 23
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 8.
                                            Terminal electron acceptor preference TbDHODH. Activity examined presence
                                            250 ÂµM DHO 100 ÂµM electron acceptor ~210 ÂµM molecular oxygen. kcatapp                                             apparent kcat obtained fixed concentration DHO (0.25 mM) oxidant.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                        Page 24
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 9.
                                            Saturation kinetics T. brucei DHODH DHO fumarate. DHO-dependent activity
                                            assayed presence 500 ÂµM fumarate fumarate-dependent activity assayed
                                            presence 250 ÂµM DHO pH 8. Vmax 8.5 sâˆ’1, Km DHO 14 ÂµM, Km                                             fumarate 80 ÂµM. kcatapp apparent kcat obtained fixed concentration                                             substrate varied. Inset: pH-dependent T. brucei DHODH activity. Activity
                                            determined presence 125 ÂµM DHO 500 ÂµM fumarate. Activity peaks pH
                                            7.8 curve indicates ionizable groups pKa values 6.3 9.2.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                    Page 25
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 10.
                                            Ping-pong kinetics T. brucei DHODH. Double-reciprocal plot DHO-dependent activity
                                            presence varying concentrations fumarate 5 nM T. brucei DHODH produce
                                            parallel lines indicative ping-pong enzyme mechanism.
NIH-PA Author Manuscript




                                                 Mol Microbiol. Author manuscript; available PMC 2010 27.
                            Arakaki et al.                                                                                      Page 26
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                            Figure 11.
                                            Inhibition TbDHODH 3,4- 3,5-dihydroxybenzoate. Activity determined varying
                                            concentrations DHO inhibitor 5 nM T. brucei DHODH. Double reciprocal plots
                                            characteristic competitive inhibition indicated concentrations 3,4
                                            dihydroxybenzoate   non-competitive inhibition 3,5 dihydroxybenzoate (b).




                         